BJU Int

1. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
   Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
   BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
   

   >> Share

   
   

   
   BMC Cancer

2. FREDMAN E, Icht O, Moore A, Bragilovski D, et al
   SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
   BMC Cancer. 2024;24:431.
   

   >> Share

   
   
3. DUAN L, Liu Z, Wan F, Dai B, et al
   Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.
   BMC Cancer. 2024;24:448.
   

   >> Share

   
   

   
   BMC Urol

4. SHIMIZU R, Morizane S, Yamamoto A, Yamane H, et al
   Assessment of the accuracy of biparametric MRI/TRUS fusion-guided biopsy for index tumor evaluation using postoperative pathology specimens.
   BMC Urol. 2024;24:79.
   

   >> Share

   
   

   
   Cancer Res

5. MURPHY S, Rahmy S, Gan D, Liu G, et al
   Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
   Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
   

   >> Share

   
   

   
   Clin Cancer Res

6. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
   Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
   Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
   

   >> Share

   
   
7. CHO H, Byun SS, Son NH, Chung JI, et al
   Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
   Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
   

   >> Share

   
   

   
   Discov Oncol

8. CHENG L, Li S, Jiang D, Zhang J, et al
   DSCAM-AS1 promotes the development of prostate cancer.
   Discov Oncol. 2024;15:113.
   

   >> Share

   
   

   
   Eur Urol

9. RUSH HL, Gilbert DC, Langley RE
   Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
   Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   

   
   Int J Cancer

10. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    

    >> Share

    
    

    
    J Magn Reson Imaging

11. BLEKER J, Roest C, Yakar D, Huisman H, et al
    The Effect of Image Resampling on the Performance of Radiomics-Based Artificial Intelligence in Multicenter Prostate MRI.
    J Magn Reson Imaging. 2023 Aug 12. doi: 10.1002/jmri.28935.
    

    >> Share

    
    
12. THIEL TA, Valentin B, Ullrich T, Boschheidgen M, et al
    Spectral Diffusion Analysis in Patients With High Risk for Prostate Cancer: A Feasibility Study.
    J Magn Reson Imaging. 2024 Apr 5. doi: 10.1002/jmri.29354.
    

    >> Share

    
    

    
    J Nucl Med

13. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    

    >> Share

    
    
14. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
    Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
    J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
    

    >> Share

    
    

    
    J Urol

15. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    

    >> Share

    
    
16. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    

    >> Share

    
    
17. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    

    >> Share

    
    
18. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    

    >> Share

    
    
19. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    

    >> Share

    
    

    
    JAMA

20. AUVINEN A, Tammela TLJ, Mirtti T, Lilja H, et al
    Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    JAMA. 2024 Apr 6:e243841. doi: 10.1001/jama.2024.3841.
    

    >> Share

    
    
21. TOSOIAN JJ, Penson DF, Chinnaiyan AM
    A Pragmatic Approach to Prostate Cancer Screening.
    JAMA. 2024 Apr 6. doi: 10.1001/jama.2024.4089.
    

    >> Share

    
    
22. MARTIN RM, Turner EL, Young GJ, Metcalfe C, et al
    Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    JAMA. 2024 Apr 6:e244011. doi: 10.1001/jama.2024.4011.
    

    >> Share

    
    

    
    Mod Pathol

23. PRENDEVILLE S, Kaur H, Ansari S, Alqaqa S, et al
    Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary-Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
    Mod Pathol. 2024 Apr 6:100489. doi: 10.1016/j.modpat.2024.100489.
    

    >> Share

    
    

    
    Mol Ther Oncol

24. BOUTIN J, Genevois C, Couillaud F, Lamrissi-Garcia I, et al
    CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer.
    Mol Ther Oncol. 2024;32:200772.
    

    >> Share

    
    

    
    Oncogene

25. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    

    >> Share

    
    

    
    PLoS Comput Biol

26. SHAH Y, Kulm S, Nauseef JT, Chen Z, et al
    Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.
    PLoS Comput Biol. 2024;20:e1011990.
    

    >> Share

    
    

    
    PLoS One

27. WU C, Zhu H, Zhang Y, Ding L, et al
    Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
    PLoS One. 2024;19:e0290753.
    

    >> Share

    
    

    
    Prostate

28. CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al
    An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
    Prostate. 2024 Apr 12. doi: 10.1002/pros.24701.
    

    >> Share

    
    
29. BROWN LK, Kanagasabai T, Li G, Celada SI, et al
    Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
    Prostate. 2024 Apr 11. doi: 10.1002/pros.24706.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share